Who was studied, and how
Four numbers in the abstract
Where each one falls
Only readable comparisons vote
Where it lands on the map
972people with dyslipidemia, in this paper
The trial randomly assignedassigned by chance
high-intensity statin therapy
the rest
Probably raised minimum FCT+1.03
Probably lowered maximum lipid arc−0.42
randomisedThe trial randomly assignedassigned by chance
combinative approach including PCSK9 antibodies and statins
the rest
Probably raised minimum FCT+1.17
randomisedthe abstract, start to end
… (5 studies with 204 participants; SMD, 1.03; 95% CI, 0.67 to 1.39; P < 0.01), as well as a combinative approach including PCSK9 antibodies and statins (3 studies with 522 participants; SMD, 1.17; 95% CI, 0.62 to 1.73; P < …
… (4 studies with 183 participants; SMD, -0.42; 95% CI, -0.65 to -0.19; P < 0.01) or the combined application of PCSK9 antibodies and statins (2 studies with 222 participants; SMD, -0.98; 95% CI, -1.26 to -0.70; P < …
← favours treatmentfavours comparator →
could be chanceMinimum FCThigh-intensity statin therapy
1.030.67–1.39
Minimum FCTcombinative approach including PCSK9 antibodies and statins
1.170.62–1.73
Maximum lipid archigh-intensity statin therapy
−0.42−0.65 to −0.19
Maximum lipid arccombined application of PCSK9 antibodies and statins
−0.98−1.26 to −0.70
StatinsPCSK9 inhibitorsLipidsAdverse events & safety
1 / 5